← Back to Search

Intravascular Imaging

Angiography with IVUS for Dialysis Access Malfunction

Phase 4
Waitlist Available
Led By William Shutze, MD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 3 months - up to 2 years
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group

Summary

The reason the investigators are doing this study is to compare the results of angiography versus angiography with intravascular ultrasound in dialysis grafts/fistulas that are blocked.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 3 months - up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 3 months - up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in characteristics of lesion within the vessel

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Angiography with IVUSExperimental Treatment1 Intervention
Evaluation with angiography and intravascular ultrasound.
Group II: AngiographyActive Control1 Intervention
Evaluation by angiography only.

Find a Location

Who is running the clinical trial?

Baylor Research InstituteLead Sponsor
206 Previous Clinical Trials
203,225 Total Patients Enrolled
William Shutze, MDPrincipal InvestigatorBaylor Health Care System
1 Previous Clinical Trials
200 Total Patients Enrolled
~15 spots leftby Nov 2025